“With this important step, we are entering the final stages of a transformation of ProMIS begun last year, first with capital formation and now with a potential listing on NASDAQ. Our lead therapeutic candidate for Alzheimer’s disease, PMN310, is progressing well, and after written pre-IND feedback from the FDA remains on track for an IND filing by the end of the year.” said Eugene Williams, Chairman and CEO of ProMIS. “We remain optimistic that clinical data in the Alzheimer’s field, specifically the pivotal trial data from Eisai’s lecanemab study, will be positive and could reverse the negative sentiment that resulted from the EMA and CMS decisions about Aduhelm. That positive data could benefit the entire AD field, including ProMIS. We also have been expanding and advancing our broader portfolio, continuing to apply the unique capabilities of our technology platform in addressing misfolded protein diseases. We believe that Nasdaq, with its tremendous depth and breadth of investment capital guided by scientific savvy, is the right stock exchange to fully appreciate the value of the ProMIS portfolio.”
The Registration Statement relating to the Common Shares that has been filed with the SEC is subject to review and comment by the SEC Staff and there can be no assurance the Registration Statement will ultimately be declared effective. The Registration Statement has also been filed on Canada’s System for Electronic Document Analysis and Retrieval (“SEDAR”). The Registration Statement is available on the SEC’s website at www.sec.gov, on the Company’s SEDAR profile at www.sedar.com and on the Company’s website.
The listing of the Company’s Common Shares on Nasdaq is subject to satisfaction of the listing requirements of Nasdaq and approval of the listing by the exchange. There can be no assurance that Nasdaq will approve the Company’s listing application in a timely manner, if at all.
ProMIS Neurosciences Inc. is a development stage biotechnology Corporation focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Corporation’s proprietary target discovery engine is based on the use of two complementary techniques. The Corporation applies its thermodynamic, computational discovery platform – ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, ProMIS is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS is headquartered in Toronto, Ontario, Canada with offices in Cambridge, Massachusetts, U.S.A. ProMIS is listed on the Toronto Stock Exchange (TSX) under symbol PMN, and on the OTCQB Venture Market under symbol ARFXF.
www.promisneurosciences.com, follow on Twitter and LinkedIn